Effects of trimetazidine in patients with acute myocardial infarction: Data from the Korean Acute Myocardial Infarction Registry

Clinical Research in Cardiology

Volumn 102, Issue 12, 2013, Pages 915-922

  Chun, Kook Jin ^a   Kim, Jeong Su ^a   Kim, Chang Hoon ^b   Kim, June Hong ^a   Park, Yong Hyun ^a   Kim, Jun ^a   Choi, Jin Hee ^a   Lee, Sang Hyun ^a   Kim, Eun Jung ^a   Yu, Dae Gon ^a   Ahn, Eun Young ^a   Jeong, Myung Ho ^c  

^a Pusan National University Yangsan Hospital   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

Acute myocardial infarction; All cause mortality; KAMIR; Major adverse cardiac event; Trimetazidine

Indexed keywords

TRIMETAZIDINE;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; STENTS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84890548694     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0611-0     Document Type: Article

References (26)

1. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A (2006) Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27:942-948
2. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM (2012) Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina - the VASCO-angina study. Int J Cardiol. doi: 10.1016/j.ijcard.2012.11.001
3. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP (2011) Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 120:59-72
4. Kirchberger I, Heier M, Wende R, von Scheidt W, Meisinger C (2012) The patient's interpretation of myocardial infarction symptoms and its role in the decision process to seek treatment: the MONICA/KORA Myocardial Infarction Registry. Clin Res Cardiol 101:909-916
5. Choi JS, Kim CS, Park JW, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW (2012) Renal dysfunction as a risk factor for painless myocardial infarction: results from Korea Acute Myocardial Infarction Registry. Clin Res Cardiol 101:795-803
6. Lee KH, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi D, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Cho JG, Park SJ (2008) Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry. Int J Cardiol 130:227-234
7. Jo HS, Park JS, Sohn JW, Yoon JC, Sohn CW, Lee SH, Hong GR, Shin DG, Kim YJ, Jeong MH, Chae SC, Hur SH, Hong TJ, Seong IW, Chae JK, Rhew JY, Chae IH, Cho MC, Bae JH, Rha SW, Kim CJ, Choi DH, Jang YS, Yoon JH, Chung WS, Seung KB, Park SJ (2011) Culprit-lesion-only versus multivessel revascularization using drug-eluting stents in patients with ST-segment elevation myocardial infarction: a Korean Acute Myocardial Infarction Registry-based analysis. Korean Circ J 41:718-725
8. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P (1994) Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37:279-288
9. Michaelides A, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P (1997) Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 13:8-14
10. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, Skibinska E, Szymczak K, Swiatek J, Winter M (2001) Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 22:2267-2274
11. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Osterspey A, Tamargo J, Zamorano JL (2006) Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 27:1341-1381
12. European Medicines Agency EMA (2012) European Commission final decision on the reassessment of trimetazidine. EMA. http://www.emea.europa.eu/docs/en-GB/ document-library/Referrals-document/Trimetazidine-31/WC500133925.pdf. Accessed 3 Sept 2012
13. Gao D, Ning N, Niu X, Hao G, Meng Z (2011) Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 97:278-286
14. Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R (2013) Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol 163:320-325
15. Iyengar SS, Rosano GM (2009) Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am J Cardiovasc Drugs 9:293-297
16. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Boger R, Rothenbacher D, Brenner H, Breitling LP (2013) Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102:193-202
17. The EMIP-FR Group (2000) Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. Eur Heart J 21:1537-1546
18. Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, Kempf C, Laperche T, Arnaud P, Sellier P, Bourguignon C, Harpey C (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77:263-273
19. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, Ovize M (2005) Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 39:893-899
20. Khan M, Meduru S, Mostafa M, Khan S, Hideg K, Kuppusamy P (2010) Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther 333:421-429
21. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H (1990) Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 11:207-212
22. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, Feuvray D (2000) Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 47:688-696
23. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P (1994) Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26:949-958
24. Kober G, Buck T, Sievert H, Vallbracht C (1992) Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 13:1109-1115
25. Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F (2007) Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 93:703-707
26. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G (2007) Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 7:143-150